Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Compared with Vitamin K Antagonists in Patients with Atrial Fibrillation and Type 2 Valvular Heart Disease: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Compared with Vitamin K Antagonists in Patients with Atrial Fibrillation and Type 2 Valvular Heart Disease: A Systematic Review and Meta-Analysis

Published:2024-08-17 Issue: Volume: Page:
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

Liang Xiaoyun,Liu Shangyu,Ji Lishuang,Ma Fangfang,Song Guoyuan,Li Fang,Liu Gang^ORCID

Funder

Natural Science Foundation of Hebei Province

Key Science and Technology Research Program of Hebei Provincial Health Commission

Industry-Academic Cooperation Foundation of Kyungnam University

Hebei Province Finance Department Project

Industry University Research Cooperation Special Project

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10557-024-07616-7.pdf

Reference32 articles.

1. Eleid MF, Nkomo VT, Pislaru SV, Gersh BJ. Valvular heart disease: new concepts in pathophysiology and therapeutic approaches. Annu Rev Med. 2023;74:155–70. https://doi.org/10.1146/annurev-med-042921-122533.

2. Sagris M, Vardas EP, Theofilis P, et al. Atrial fibrillation: pathogenesis, predisposing factors, and genetics. Int J Mol Sci. 2021;23(1):6. https://doi.org/10.3390/ijms23010006.

3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e876–94. https://doi.org/10.1161/cir.0000000000001062.

4. Doi K, Ogawa H, Ishigami K, et al. Impact of valvular heart disease on mortality, thromboembolic and cardiac events in japanese patients with atrial fibrillation - the Fushimi AF Registry. Circ J. 2020;84(5):714–22. https://doi.org/10.1253/circj.CJ-19-1158.

5. Melgaard L, Overvad TF, Jensen M, et al. Thromboembolic risk in nonanticoagulated patients with atrial fibrillation and valvular heart disease. JACC Clin Electrophysiol. 2020;6(13):1672–82. https://doi.org/10.1016/j.jacep.2020.07.005.